BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Comparative effectiveness in multiple sclerosis: A methodological comparison

Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Patrizia Sola

2023-03-01

BACKGROUND: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trial..

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S Sharmin, C Malpas, J Lechner-Scott, M Slee, P McCombe, S Vucic, E Butler, S Hodgkinson, M Barnett, O Skibina, A van der Walt, K Buzzard, C Shaw, A Kermode, B Taylor, N Shuey, R Macdonell, H Butzkueven, T Kalincik

2022-12-01

BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); how..

Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study

Marianna Vitkova, Ibrahima Diouf, Charles Malpas, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Vahid Shaygannejad, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Catherine Larochelle, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison

2022-06-14

BACKGROUND AND OBJECTIVES: The severity of multiple sclerosis (MS) varies widely among individuals. Understanding the determinants..

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

M Lefort, S Sharmin, JB Andersen, S Vukusic, R Casey, M Debouverie, G Edan, J Ciron, A Ruet, J De Seze, E Maillart, H Zephir, P Labauge, G Defer, C Lebrun-Frenay, T Moreau, E Berger, P Clavelou, J Pelletier, B Stankoff

2022-05-30

BACKGROUND: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several obs..

The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis

Federico Frascoli, Izanne Roos, Charles B Malpas, Tomas Kalincik

2022-03-15

Based on reported trends in relapse incidence among patients with relapsing-remitting multiple sclerosis, an original model for th..

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, Eva Kubala Havrdova, Raed Alroughani, Guillermo Izquierdo, Serkan Ozakbas, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, Francois Grand'Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz

2021-09-18

INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting mult..

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis

Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau Madueno, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach

2021-08-31

OBJECTIVE: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactiv..

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

Johanna B Andersen, Sifat Sharmin, Mathilde Lefort, Nils Koch-Henriksen, Finn Sellebjerg, Per Soelberg Sorensen, Claudia C Hilt Christensen, Peter Rasmussen, Michael B Jensen, Jette L Frederiksen, Stephan Bramow, Henrik K Mathiesen, Karen Schreiber, Dana Horakova, Eva K Havrdova, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Francesco Patti

2021-06-08

BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsi..

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva K Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi

2020-09-01

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies re..

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

Amy Kunchok, Jeannette Lechner-Scott, Franco Granella, Maria Trojano, Raed Alroughani, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Marco Onofrj, Serkan Ozakbas, Guillermo Izquierdo, Pierre Grammond, Jose Luis Sanchez-Menoyo, Bart Van Wijmeersch, Cavit Boz, Eugenio Pucci, Pamela McCombe, Francois Grand'Maison, Daniele Spitaleri, Steve Vucic

2020-07-08

BACKGROUND: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging ..

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Le Minh, Charles Malpas, Sifat Sharmin, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Catherine Larochelle, Raed Alroughani, Roberto Bergamaschi, Patrizia Sola, Diana Ferraro, Pierre Grammond, Francois Grand' Maison

2020-06-15

BACKGROUND: Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values re..

Early clinical markers of aggressive multiple sclerosis

Charles B Malpas, Ali Manouchehrinia, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Sara Eichau, Roberto Bergamaschi, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Francois Grand'Maison, Serkan Ozakbas, Vincent Van Pesch

2020-05-01

Patients with the ‘aggressive’ form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Di..

The MSBase registry: Informing clinical practice

Tomas Kalincik, Helmut Butzkueven

2019-12-01

Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decision..